NCT00378326View on ClinicalTrials.gov

Immunotherapy of the Paraneoplastic Syndromes

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Paraneoplastic Syndromes
Interventions
DRUG

Tacrolimus

Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone

Trial Locations (1)

10021

Rockefeller University Hospital, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT00378326 - Immunotherapy of the Paraneoplastic Syndromes | Biotech Hunter | Biotech Hunter